Skip to content

COVID-19 Infection in Healthcare Workers

COVID-19 Infection in Healthcare Workers: a Cohort Study

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04386759
Acronym
HOP-COVID
Enrollment
1858
Registered
2020-05-13
Start date
2020-05-18
Completion date
2021-07-26
Last updated
2022-02-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COVID-19

Keywords

COVID-19, Healthcare workers, Incidence, Risk factors, Nosocomial infection

Brief summary

Introduction: The SARS-Cov-2 outbreak in France and the concomitant massive increase in the number of cases requiring hospital management create a major risk of COVID-19 infection for hospital staff. In addition to nosocomial transmission, the health care workers (HCWs), defined as persons serving in health care settings who have the potential for direct or indirect exposure to patients or infectious materials, are also exposed to community transmission. Whether HCWs acquire infection at work or in the community is important to adapt protection measures. A few studies investigated COVID-19 infection among medical and nursing personnel. However, none have analyzed all categories of hospital staff. As of April 9, 2020, a total of 9,282 US HCWs with confirmed COVID-19 had been reported to CDC (US), however description of occupational activities was not available. Therefore, limited information is available about COVID-19 infection among HCWs. Thus, the objectives of the sdudy are to estimate the incidence of symptomatic SARS-CoV-2 infection in HCWs in five university hospitals (including geriatric hospitals) of the great Paris area and to estimate both nosocomial and community risk factors. Method: A prospective and retrospective cohort study that includes all hospital staff (including medical and nursing personnel, health care managers, laboratory, radiology, reception staffs, stretcher-bearers, etc.) working in different departments of five university hospitals (acute medical centers and geriatric hospitals) in the great Paris area (9 000 HCWs). Incidence of symptomatic SARS-CoV-2 infection will be estimated with its 95%CI. Individual and contextual risk factors will be analyzed using multilevel multivariate logistic regression modelling to account for clustering and confounding. Conclusion This study should make it possible to better characterize SARS-Cov-2 contamination of HCWs and to estimate the share of nosocomial transmission.

Detailed description

Details for Study design section Time perspective : Retrospective and prospective cohort study. Up to protocol v2.0: Data from healthcare workers with COVID+ diagnostic at the time of inclusion will only be collected retrospectively. In contrast, data from healthcare workers free from infection will be collected prospectively. From protocol v3.0: Recruitment of healthcare workers will be prospective. A retrospective collection of exposures during the 15 days preceding the RT-PCR or the antigenic test for COVID diagnosis will be performed.

Interventions

OTHERCohort

None. Only implementation of a cohort with data collection via individual self-questionnaires and administrative services for contextual data.

Sponsors

Assistance Publique - Hôpitaux de Paris
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
OTHER

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* Hospital staff working in any of the 5 hospitals participating in the study, * Of legal age, * With or without a previous diagnosis of COVID-19 infection, * Patient with a SARS-CoV-2 screening by RT-PCR or antigenic test (from version 3.0 of the protocol) * Not opposed to participating in the research

Exclusion criteria

* Unable or unwilling to complete the non-opposition * Unable or unwilling to complete an online self-questionnaire (eCRF) * Opposition to participate in research

Design outcomes

Primary

MeasureTime frameDescription
SARS-COV-2 infectionUp to 3 monthsThe primary endpoint will be the occurrence of confirmed (RT-PCR or antigenic test or work stopping) SARS-CoV-2 infection.

Secondary

MeasureTime frameDescription
SARS-COV-2 incidence regarding hospitals, assigned services and professionUp to 3 months maximumInformation collected by a self questionnaire and service datas
Individual and contextual risks factorsUp to 3 months maximumRisks factor are collected by a self questionnaire and service datas

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 10, 2026